Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022
Authors' conclusion
The procurement of non-insulin antidiabetic medicines in China has increased a lot from 2015 to 2022. In terms of DDDs per patient, sulphonylurea ranked first, followed by metformin. The procurement of new drugs increased greatly. A large regional disparity existed in medicine usage and patterns.
Study context
- Population
- Non-insulin antidiabetic medicines (29 medicines, nine subgroups) procured in seven regions of China, 2015–202229 medicines
- Outcome
- DDDs of non-insulin antidiabetic medicines procured per patient with diabetes
- Follow-up
- 2015 to 2022
Methodological detailsnational procurement data, trend analysis
- National procurement data
- Trend analysis
Main finding
As reported in the abstract
DDDs per patient, nationwide
Defined daily doses (DDDs) per patient, 2015
14.45
DDDs per patient, 2022
47.37
Observational data: associations, not effects.
Further findings
DDDs per patient by subgroup · 2015 to 2022
- SU, 2015 to 2022 (relative change)
- 7.04 to 15.39 (119%)
- Biguanides, 2015 to 2022 (relative change)
- 3.28 to 11.11 (239%)
- New drugs (DPP-4i, SGLT2i, GLP-1 RA): relative change
- >5000%
- SGLT2i, 2015 to 2022 (relative change)
- 0.08 to 5.03 DDDs (6662%)
Regional relative change
- Southwest region (highest)
- 319%
- Southern region (lowest)
- 118%
Regional disparity · 2022
- Biguanide (lowest)
- 1.19
- TZD (highest)
- 2.21
Original publication
Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022. Diabetes Obes Metab. Published 15 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →